Simulations Plus Stock: Buying On Long-Term Silico Drug-Development (NASDAQ:SLP)

Simulations Plus, Inc. ( SLP ) is a pure-play in silico platform for model-informed, non-animal drug development. The company combines software systems with services for clients. For example, they offer GastroPlus, ADMET Predictor, MonolixSuite, DILIsym, and NAFLDsym, with services in QSP modeling, clinical pharmacology, training, and medical communications. That way, SLP'sMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Na ...